Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of TL118 in patients with NTRK fusion-positive tumors
CTR20222613Phase 2Active
- Sponsor
- Taolue Biopharma
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TL118 in TRK fusion cancer (NTRK), sponsored by Taolue Biopharma. Started Mar 2023; status: active.
02
Drugs
TL118
03
Conditions
TRK fusion cancer (NTRK)
Beyond the preview
Go deeper on CTR20222613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222613.